Linezolid: An effective, safe and cheap drug for patients failing multidrug-resistant tuberculosis treatment in India

European Respiratory Journal

Volumn 39, Issue 4, 2012, Pages 956-962

  Singla, R ^a   Caminero, J A ^b,c   Jaiswal, A ^a   Singla, N ^a   Gupta, S ^a   Bali, R K ^a   Behera, D ^a  

^a Lala Ram Sarup Institute of Tuberculosis and Respiratory Diseases   (India)

^b HOSPITAL UNIVERSITARIO DE GRAN CANARIA DR NEGRÍN   (Spain)

^c INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

Author keywords

Extensively drug resistant; Linezolid; Multidrug resistant tuberculosis

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHIONAMIDE; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANEMIA; ANOREXIA; ARTICLE; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEARING LOSS; HUMAN; INDIA; LOW DRUG DOSE; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA AND VOMITING; NEURITIS; OPTIC NEURITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; SPUTUM SMEAR; TREATMENT OUTCOME;

ACETAMIDES; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; DRUG COSTS; DRUG THERAPY, COMBINATION; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; FLUOROQUINOLONES; HUMANS; INDIA; MALE; MIDDLE AGED; OXAZOLIDINONES; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84860330843     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00076811     Document Type: Article

References (32)

1. World Health Organization. The global MDR-TB and XDR-TB response plan 2007-2008. World Health Organization Document; WHO/HTM/STB/2007.2007.387. pp. 1-51. Geneva, WHO, 2007.
2. Jacobson KR, Tierney DB, Jeon CY, et al. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis 2010; 51: 6-14.
3. Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J 2009; 33: 871-881.
4. Jeon DS, Kim DH, Kang HS, et al. Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 2009; 13: 594-600.
5. Orenstein EW, Basu S, Shah NS, et al. Treatment outcome among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 153-161.
6. Johnston JC, Shahidi NC, Sadatsafavi M, et al. Treatment outcomes of multidrug-reistant tuberculosis: a systematic review and metaanalysis. PLoS One 2009; 4: e6914.
7. Chiang CY, Enarson DA, Yu MC, et al. Outcome of pulmonary multidrug-resistant tuberculosis: a 6-yr follow-up study. Eur Respir J 2006; 28: 980-985. (Pubitemid 46331968)
8. Chan ED, Laurel V, Strand MJ, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004; 169: 1103-1109. (Pubitemid 38624789)
9. Migliori GB, Lange C, Centi R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 2008; 31: 1155-1159.
10. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 113-119.
11. Migliori GB, Eker B, Richardson MD, et al. A retrospectve TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 2009; 34: 387-393.
12. Ntziora F, Falagas ME. Linezolid for the treatment of patients with mycobacterial infections: a systematic review. Int J Tuberc Lung Dis 2007; 11: 606-611. (Pubitemid 46868619)
13. Udwadia ZF, Sen T, Moharil G. Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective. Eur Respir J 2010; 35: 936-938.
14. Park IN, Hong SB, Oh YM, et al. Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis. J Antimicrob Chemother 2006; 58: 701-704. (Pubitemid 44288145)
15. Singla R, Sarin R, Khalid UK, et al. Seven-year DOTS-Plus pilot experience in India: results, constraints and issues. Int J Tuberc Lung Dis 2009; 13: 976-981.
16. Kim SJ, Espinal MA, Abe C, et al. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis 2004; 8: 1157-1158. (Pubitemid 39201267)
17. Laserson KF, Thorpe LE, Leimane V, et al. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2005; 9: 640-645. (Pubitemid 40826156)
18. National Tuberculosis Association. Diagnostic standard and classification of tuberculosis. New York, National Tuberculosis Association, 1961.
19. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194: 479-485. (Pubitemid 44162659)
20. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-2154. (Pubitemid 44914009)
21. Caminero JA. Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding. Int J Tuberc Lung Dis 2010; 14: 382-390.
22. Kwon YS, Kim YH, Chung MP, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis 2008; 47: 496-502.
23. Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment of extensively drug-resistant tuberculosis. N Engl J Med 2008; 359: 563-574.
24. Hwang SS, Kim HR, Kim HJ, et al. Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB. Eur Respir J 2009; 33: 581-585.
25. Chan ED, Strand MJ, Iseman MD. Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB. Clin Infect Dis 2009; 48: e50-e52.
26. Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis. Am J Respir Crit Care Med 2008; 178: 1075-1082.
27. Cynamon MH, Klemens SP, Sharpe CA, et al. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43: 1189-1191. (Pubitemid 29214745)
28. Schecter GF, Scott C, True L, et al. Linezolid in the treatment of multidrug-resistant tuberculosis. Clin Infect Dis 2010; 50: 49-55.
29. Condos R, Hadgiangelis N, Leibert E, et al. Case series report of a linezolid-containing regimen for extenseively drug-resistant tuberculosis. Chest 2008; 134: 187-192. c (Pubitemid 352008783)
30. Eker B, Ortmann J, Migliori GB, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008; 14: 1700-1706.
31. Koh WJ, Kwon OJ, Gwak H, et al. Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 2009; 64: 388-391.
32. Dravniece G, Cain KP, Holtz TH, et al. Adjunctive resectional lung surgery for extensively drug-resistant tuberculosis. Eur Respir J 2009; 34: 180-183.